Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 40,007 | 9,065 | 66,854 | 13,578 |
| Research and development | 91,178 | 54,081 | 199,870 | 98,253 |
| Selling, general and administrative | 289,375 | 196,858 | 557,896 | 364,734 |
| Total operating expenses | 420,560 | 260,004 | 824,620 | 476,565 |
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
| Interest income | 7,104 | 8,227 | 15,347 | 17,597 |
| Interest expense | (7,940) | (3,264) | (15,759) | (6,561) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s SG&A?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported SG&A of $289.38M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s SG&A increased by 47.0% year-over-year, from $196.86M to $289.38M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Madrigal Pharmaceuticals, Inc.'s SG&A has grown at a 156.7% compound annual growth rate (CAGR), from $48.13M to $813.83M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude